Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review
Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F.. JAMA neurology, 2022-03-01
Topic: Amyloid, tau and blood-test diagnosis
Apolipoprotein E (ApoE) ε4 genotype was the main risk factor for both ARIA types; ARIA-E incidence was further associated with treatment dose, affecting the 55% of ApoE ε4 carriers in the high-dose aducanumab treatment group. Conclusions and relevance Evidence suggests that ARIAs are frequent, mostly asymptomatic collateral events of amyloid-modifying therapies, highlighting the need for standardized clinical and neuroradiological management protocols in real-world clinical settings.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022). Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review. JAMA neurology. https://doi.org/10.1001/jamaneurol.2021.5205
Vancouver
Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review. JAMA neurology. 2022. doi:10.1001/jamaneurol.2021.5205. PMID: 35099507.
BibTeX
@article{filippi2022-35099507,
author = {Filippi, M. and Cecchetti, G. and Spinelli, E. G. and Vezzulli, P. and Falini, A. and Agosta, F.},
title = {{Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review}},
journal = {JAMA neurology},
year = {2022},
doi = {10.1001/jamaneurol.2021.5205},
pmid = {35099507},
url = {https://doi.org/10.1001/jamaneurol.2021.5205}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Apolipoprotein E (ApoE) ε4 genotype was the main risk factor for both ARIA types; ARIA-E incidence was further associated with treatment dose, affecting the 55% of ApoE ε4 carriers in the high-dose aducanumab treatment group.
- Conclusions and relevance Evidence suggests that ARIAs are frequent, mostly asymptomatic collateral events of amyloid-modifying therapies, highlighting the need for standardized clinical and neuroradiological management protocols in real-world clinical settings.
Why it matters
This review found that amyloid-related imaging abnormalities are common side effects of amyloid-targeting antibody treatments, and that APOE epsilon4 carriers were at highest risk, with 55% of epsilon4 carriers in the high-dose aducanumab group affected. It highlights the need for standardized monitoring, not a cure or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designsystematic review
- Effect size54.7%; 6.1% to 39.3%; 13.8% to 25.6%
- Evidence strengthHigh
How this study scored 72/100
Published in a leading specialty journal, and it is a systematic review of all the studies on the question. Scored zero for sample size because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | 5 / 7 | Cited 183 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 30.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 18.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 19 other studies in this library |
| Still being cited | 3 / 4 | Cited 145 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Federica Agosta: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | IRCCS Ospedale San Raffaele: institution h-index 731 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35099507) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
19 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.